Renal Cell Carcinoma
Medical Education
Educational Series Episode 1 – The role of the Gastroenterologist in aRCC
In our inaugural episode, we highlight the role of the gastroenterologist in managing advanced renal cell carcinoma (aRCC). We delve into the critical management of treatment-related adverse events (trAE) associated with aRCC therapy, with a specific emphasis on gastrointestinal adverse events.
DRSC-UK-000445 | April 2024
Educational Series Episode 2 – The role of the Cardiologist in aRCC
The second episode discusses the role of a cardiologist in managing advanced renal cell carcinoma (aRCC). We focus on the important management of treatment-related adverse events associated with aRCC therapy, highlighting cardiovascular (CV) adverse events.
DRSC-GB-00397 | July 2024
Real-world evidence module
Brain metastases in renal cell carcinoma (RCC)
This module provides an overview of real-world evidence studies on brain metastases in renal cell carcinoma (RCC). It covers the background of brain metastases in RCC and includes ongoing clinical trials in patients with renal cell carcinoma and brain metastases. Additionally, it focuses on selected real world evidence studies recently published.
CMX-UK-005955 | October 2024
Real-world evidence module
Bone metastases in renal cell carcinoma (RCC)
This module offers an overview of real-world evidence studies on bone metastases in renal cell carcinoma (RCC). It covers the background of bone metastases in RCC and includes ongoing clinical trials in patients with renal cell carcinoma and brain metastases. Additionally, it focuses on selected real-world evidence studies recently published.
CMX-UK-005956 | October 2024
Real-world evidence module
Non-clear cell renal cell carcinoma (nccRCC)
This module focuses on non-clear cell renal cell carcinoma (RCC). It includes background information, an overview of real-world evidence studies and ongoing clinical trials in patients with non-clear cell renal cell carcinoma, and selected summaries of the most recent real-world evidence studies.
DRSC-UK-000667 | October 2024
Real-world evidence module
First line combination treatment in advanced renal cell carcinoma (aRCC)
This module offers an overview of first-line (1L) therapy for advanced renal cell carcinoma (aRCC). It covers the background of aRCC 1L therapy, prognosis factors, and international guidelines. Additionally, it provides an overview of real-world evidence studies and ongoing clinical trials of 1L combination therapy in patients with aRCC. The module also includes selected summaries of the most recent real-world evidence studies and ongoing clinical trials in patients with renal cell carcinoma treated with combination therapy in 1L.
DRSC-UK-000666 | October 2024
Real-world evidence module
Intermittent or alternative dosing schedules for patients with aRCC
This module focuses on intermittent or alternative dosing schedules for patients with advanced renal cell carcinoma (aRCC). It includes an introduction to intermittent or alternative dosing and provides an overview of Phase 2 studies on the efficacy and safety of therapies following intermittent dosing. Additionally, it features selected summaries of the most recent real-world evidence studies on this topic.
DRSC-UK-000668 | October 2024
